You are viewing an incomplete version of our website. Please click to reload the website as full version.

BRAF antibody (V-Raf Murine Sarcoma Viral Oncogene Homolog B1)

Details for Product anti-BRAF Antibody No. ABIN968991, Supplier: Log in to see
Antigen
  • B-Raf
  • braf1
  • rafb1
  • b-raf1
  • sierrabraf
  • BRAF
  • 9930012E13Rik
  • AA120551
  • AA387315
  • AA473386
  • B-raf
  • Braf-2
  • Braf2
  • C230098H17
  • C87398
  • D6Ertd631e
  • Braf
  • HYPT11
  • SME
  • Sm-E
  • B-RAF1
  • BRAF1
  • NS7
  • RAFB1
  • C-RMIL
  • RMIL
  • v-raf murine sarcoma viral oncogene homolog B
  • v-raf murine sarcoma viral oncogene homolog B1
  • Braf transforming gene
  • Braf transforming gene, related sequence 1
  • small nuclear ribonucleoprotein polypeptide E
  • braf
  • BRAF
  • LOC100219601
  • Braf
  • Braf-rs1
  • SNRPE
Alternatives
anti-Human BRAF antibody for Western Blotting
Reactivity
Human, Mouse (Murine)
405
87
69
13
10
4
4
3
1
1
1
1
Host
Mouse
310
91
3
2
Clonality (Clone)
Monoclonal ()
Conjugate
This BRAF antibody is un-conjugated
20
20
20
17
17
17
3
3
3
3
3
3
3
3
3
3
3
Application
Immunocytochemistry (ICC), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
264
215
149
82
62
43
39
22
11
8
4
3
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen Purified recombinant fragment of human BRAF expressed in E. coli.
Clone 1H12
Isotype IgG1
Purification Ascites
Alternative Name BRAF (BRAF Antibody Abstract)
Background BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1, RAFB1, B-RAF1, FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.
Molecular Weight 87 kDa
Gene ID 673
HGNC 673
Pathways MAPK Signaling, RTK Signaling, Neurotrophin Signaling Pathway
Application Notes Recommended Dilution:
ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000, ICC: 1/200 - 1/1000
Not yet tested in other applications.
Determining optimal working dilutions by titration test.
Restrictions For Research Use only
Format Liquid
Buffer Ascitic fluid containing 0.03 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Store at 4 °C or at -20 °C for long term.
Supplier Images
Immunocytochemistry (ICC) image for anti-BRAF antibody (V-Raf Murine Sarcoma Viral Oncogene Homolog B1) (ABIN968991) Figure 1: Confocal immunofluorescence analysis of MCF-7 (left) and HepG2 (right) cell...
Immunohistochemistry (IHC) image for anti-BRAF antibody (V-Raf Murine Sarcoma Viral Oncogene Homolog B1) (ABIN968991) Figure 2: Immunohistochemical analysis of paraffin-embedded human testis tissues usin...
Western Blotting (WB) image for anti-BRAF antibody (V-Raf Murine Sarcoma Viral Oncogene Homolog B1) (ABIN968991) Figure 3: Western blot analysis using BRAF mouse mAb against Hela (1), HL60 (2), HepG...
Product cited in: Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, 2008 (PubMed).

Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas, Nistal, Santisteban: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, 2006 (PubMed).